Literature DB >> 16211336

Successful retreatment with infliximab in patients with prior severe infusion reactions.

Imad Uthman1, Zahi Touma, Jinane El-Sayyad, Fares Zaitoun.   

Abstract

Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16211336     DOI： 10.1007/s10067-005-0029-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  9 in total

1.  Long term safety of infliximab.

Authors:  T F Schaible
Journal:  Can J Gastroenterol       Date:  2000-09       Impact factor: 3.522

2.  Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists.

Authors:  R Y Lin; A Curry; G R Pesola; R J Knight; H S Lee; L Bakalchuk; C Tenenbaum; R E Westfal
Journal:  Ann Emerg Med       Date:  2000-11       Impact factor: 5.721

3.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

4.  Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.

Authors:  Subra Kugathasan; Michael B Levy; Kia Saeian; Sotirios Vasilopoulos; Joseph P Kim; Devang Prajapati; Jeanne Emmons; Alfonso Martinez; Kevin J Kelly; David G Binion
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

Review 5.  Safety overview of new disease-modifying antirheumatic drugs.

Authors:  John J Cush
Journal:  Rheum Dis Clin North Am       Date:  2004-05       Impact factor: 2.670

6.  Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number.

Authors:  Michael J Wasserman; Deborah A Weber; Judith A Guthrie; Vivian P Bykerk; Peter Lee; Edward C Keystone
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

7.  The incidence and management of infusion reactions to infliximab: a large center experience.

Authors:  Adam Cheifetz; Michelle Smedley; Sara Martin; Monica Reiter; Grace Leone; Lloyd Mayer; Scott Plevy
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

Review 8.  The histamine-cytokine network in allergic inflammation.

Authors:  Gianni Marone; Francescopaolo Granata; Giuseppe Spadaro; Arturo Genovese; Massimo Triggiani
Journal:  J Allergy Clin Immunol       Date:  2003-10       Impact factor: 10.793

9.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Authors:  Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682
  9 in total
  1 in total

1.  The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.

Authors:  Khaled M Musallam; Thurayya Arayssi; Ali T Taher; Nadim Kanj; Imad Uthman
Journal:  Rheumatol Int       Date:  2008-12-04       Impact factor: 2.631
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.